Eagle Pharmaceuticals Appoints Abhinav Jain To Board Under Nantahala Agreement

Eagle Pharmaceuticals, Inc. announced plans to appoint Abhinav Jain as an independent member of its Board of Directors, pending customary onboarding procedures. Jain will serve as a Class III director through the Company’s 2026 Annual Meeting of Stockholders and will join the Compensation Committee and Nominating and Corporate Governance Committee.

“We look forward to welcoming Abi to our Board and to benefiting from his perspectives and experiences. We believe Abi’s strategic insights will be beneficial as we continue the Company’s strategy to enhance value for our stakeholders,” said Michael Graves, Chief Executive Officer of Eagle and Executive Chairman of the Board of Directors. 

The appointment is part of a cooperation agreement with Nantahala Capital Management, LLC, Eagle’s largest shareholder, which holds approximately 38% of the company’s outstanding shares. As part of the agreement, Eagle also committed to appointing a second independent director to its Board no later than May 15, 2026.

Mr. Jain brings a strong investment and finance background to Eagle’s Board. Currently an Analyst at Nantahala, he focuses on specialty and generic pharmaceutical investments. His prior experience includes private equity and structured credit at Angelo, Gordon & Co. He holds an S.B. in Chemical-Biological Engineering from MIT and an MBA with honors in Finance and Entrepreneurial Management from The Wharton School, University of Pennsylvania.